tbuckley/cabot-search huggingface dataset:
Prognostic impact of angiogenic markers in tumor and stromal cells in non-small cell lung cancer (NSCLC)
Authors: T. Donnem, S. Al-Saad, K. Al-Shibli, M. P. Delghandi, M. Persson, M. Nilsen, L. T. Busund, R. M. Bremnes
Journal: Journal of Clinical Oncology (2007)

10596 Background: The vascular endothelial growth factors (VEGFs) -A, -C, -D and the vascular endothelial growth factor Receptors (VEGFRs) -1, -2 and -3 are important molecular markers in angiogenesis and lymphangiogenesis. This study elucidates the prognostic significance of these molecular markers in tumor cells as well as in the tumor stroma of resected NSCLC tumors. Methods: Tumor tissue samples from 335 resected patients with stage I to IIIA were obtained and tissue microarrays were constructed from duplicate cores of tumor cells and surrounding stromal tissue from each resected specimen. Immunohistochemistry was used to evaluate the expression of each molecular marker. Results: In univariate analyses, high tumor cell expression of VEGF-A (P = .0005), VEGFR-1 (P = .013), VEGFR-2 (P = .006) and VEGFR-3 (P = .0003), were negative prognostic indicators for disease-specific survival (DSS). The most significant correlations between angiogenic marker expression and DSS were observed in patients with T2 stage and/or with sqamous cell carcinomas. In tumor stroma, however, high expression of VEGF-A (P = .017), VEGF-C (P = .003), VEGF-D (P = .009), VEGFR-1 (P = .01) and VEGFR-2 (P = .019), correlated with good prognosis. In multivariate analyses, high expression in tumor cells of VEGFR-3 (P = .007) was an independent negative prognostic factor for DSS, whereas high VEGF-C (P = .004) expression in stromal cells had an independent positive impact on survival. Conclusions: While high tumor cell expression of VEGFR-3 is an independent predictor of reduced survival in primary NSCLC, high VEGF-C expression in stromal cells is, in contrast, a favorable independent prognostic indicator. No significant financial relationships to disclose.
PLATELET DERIVED GROWTH FACTOR PROMOTES THE WARBURG EFFECT IN PULMONARY ARTERIAL SMOOTH MUSCLE CELLS VIA ACTIVATING THE PHOSPHATIDYL INOSITOL 3-KINASE SIGNALING PATHWAY AND HYPOXIA-INDUCIBLE FACTOR 1-ALPHA
Authors: Yunbin Xiao, Hongyan Peng, Xuping Qin, Zhi Chen, Chenliang Hong, Xicheng Deng, Jinwen Luo
Journal: Journal of the American College of Cardiology (2017)
INTEGRATED USE OF PERFUSION SPECT/CTA FUSION IMAGING AND PULMONARY BALLOON ANGIOPLASTY FOR CHRONIC PULMONARY THROMBOEMBOLISM
Authors: Ryoji Yanagisawa, Kenneth Fetterly, Geoffrey Johnson, Thomas Foley, Eric Williamson, Rajiv Gulati, Gurpreet Sandhu, Robert Frantz
Journal: Journal of the American College of Cardiology (2017)
A phase II study of weekly irinotecan and capecitabine for <i>chemo-naïve</i> patients with advanced NSCLC
Authors: J. J. Lee, J. Y. Han, D. H. Lee, H. Y. Kim, H. G. Lee, S. Y. Lee, E. H. Shin, J. S. Lee
Journal: Journal of Clinical Oncology (2004)

7261 Background: Encouraged by the synergistic antitumor activity without overlapping major toxicity, we evaluated the efficacy of irinotecan (I) plus capecitabine (X) combination in patients with previously-treated NSCLC (Clin Cancer Res 9:5909–14, 2003). In that study, those who received one prior regimen and those with longer than 6-month treatment-free interval had significantly higher response rates than those who received 2 or more regimens (4/18 vs. 0/17, p=0.04) and those with shorter treatment-free interval (3/6 vs. 1/29, p=0.001), respectively. We conducted this phase II study to further evaluate the efficacy and toxicity of IX regimen in chemo-naïve NSCLC patients. Methods: Eligible patients were required to have no prior chemotherapy, measurable lesion(s), ECOG PS of 0–2, adequate organ functions and signed informed consent. The treatment consisted of I 90 mg/m2 IV on days 1 and 8 plus X 1,000 mg/m2 p.o., b.i.d. on days 1–14 of a 21-day cycle up to maximum of 12 cycles, or until disease progression or unacceptable toxicity. Results: Between 7/2003 and 9/2003, 39 patients (M/F, 34/5; median age, 60.5 years) were enrolled; 13 (33%) had squamous cell carcinoma (SQC) and 29 (74%) had stage IV. Of 36 evaluable pts, 15 (42%) had PR, 15 (42%) had SD, 6 (17 %) had PD. SQC tended to show higher response rate than non-SQC (6/11 vs. 9/25). With mean relative dose intensity of 95% for I and 94% for X, IX was extremely well tolerated with G3/4 hematologic and non-hematologic toxicities reported in only 2 and 11 patients (5 HFS, 2 vomiting, 2 diarrhea, 2 infection). The median survival duration has not been reached yet. Conclusions: Weekly IX, a novel new regimen, has shown promising anti-tumor activity comparable to other regimens for NSCLC, but with minimal toxicity. We continue to accrue more SQC patients to better estimate the response rate. (Supported in part by National Cancer Center Grant 0210140) No significant financial relationships to disclose.
Primary chemotherapy, stereotactic radiosurgery, or whole brain radiotherapy in non-small cell lung cancer (NSCLC) patients with asymptomatic brain metastases
Authors: K. Kim, J. Lee, M. Chang, J. Uhm, J. A. Yun, S. Yi, Y. Park, J. Ahn, K. Park, M. Ahn
Journal: Journal of Clinical Oncology (2009)

e19063 Background: Approximately 25 to 30% of patients with lung cancer develop brain metastases at some stage and 12∼18% at the time of initial presentation. Whole brain radiotherapy (WBRT) has long been a mainstay of treatment of brain metastases. Another treatment approach, Stereotactic radiosurgery (SRS) is a method of delivering high doses of focal irradiation to a tumor while minimizing the irradiation to the adjacent normal tissue. However, the prognosis of NSCLC patients with asymptomatic brain metastases, who are not treated with SRS or WBRT, has not been fully investigated yet. This study aimed to analyze the outcome for various treatment modalities in NSCLC patients with asymptomatic brain metastases. Methods: We reviewed the medical records of 129 patients with a histopathologically proven NSCLC and a synchronous brain metastases between January 2003 and December 2007. The patients were categorized as primary chemotherapy, primary SRS, and primary WBRT group: primary chemotherapy (78 patients), primary SRS (24 patients), and primary WBRT (27 patients). Results: With median follow-up of 30.0 months (7.2 -70.7), the median overall survival (OS) for the entire patients was 15.6 months (0.5–50.7) and the progression free survival (PFS) was 6.1 months (0.3- 53.0). The OS was 22.4m for primary SRS group, 13.9m for primary chemotherapy group, and 17.7m for primary WBRT group; p=0.86). However, patients treated with primary SRS showed trend toward prolonged survival compared to those of primary WBRT p=0.06). Subset analysis of 110 adenocarcinoma patients showed that the median OS for patients treated with primary SRS was longer than those of primary WRBT (29.3m vs 17.7m p=0.01) or primary chemotherapy (29.3m vs 14.6m p=0.04). Conclusions: These results suggest that for NSCLC patients with asymptomatic brain metastases at first diagnosis, SRS rather than primary chemotherapy or WBRT might be considered as initial treatment, especially for patients with adenocarcinoma. No significant financial relationships to disclose.
What is the probability of a positive bone scan (+BS) in patients with a rising PSA after radical prostatectomy (RP): A new nomogram
Authors: Z. A. Dotan, M. W. Kattan, F. J. Bianco, F. Rabbani, J. A. Eastham, H. I. Scher, C. Hui-Ni, H. Schoder, H. Hricak, P. T. Scardino
Journal: Journal of Clinical Oncology (2004)

4553 Background: Physicians often order bone scans periodically to assess for metastases in patients with a rising PSA after RP (biochemical recurrence, BCR), but most scans are negative. We studied pre- and postoperative characteristics of patients to find factors predictive of a positive scan. Methods: From our SPORE prostate cancer database we identified all patients with BCR (3 subsequent peaks in PSA ≥0.1 ng/ml) after RP. We analyzed the following features at the time of each BS for their association with a positive scan: preoperative PSA, neoadjuvant hormonal therapy (NHT), time to BCR, pathologic findings (surgical margin, extracapsular extension, seminal vesicle invasion, lymph node metastases, and pathologic Gleason score), PSA level before the BS (trigger PSA), PSA doubling time (PSA DT), and time from BCR to BS were incorporated into a predictive model. Results: There were 927 scans in 330 patients with BCR. We excluded 318 scans done while the patient was on androgen deprivation therapy. Of the 609 eligible scans, only 84 (13.8%) were positive for metastases. In multivariate analysis trigger PSA (P=0.014), NHT (P=0.03), and time from BCR to bone scan (P=0.05) predicted a +BS. Pathologic variables and PSA DT did not add to the accuracy of the model. A nomogram for predicting the bone scan result was constructed with a concordence index of 0.9. A policy of ordering a BS only when the probability of a +BS is >15% would eliminate 76% of the scans currently ordered in patients with BCR after RP and will lead to a significant savings in the health care expenses. Conclusions: Patients with BCR after RP have a low frequency of +BS (13.8%). Trigger PSA, NHT, and time from BCR to scan were significant predictors of a +BS. A highly accurate nomogram can be used to select patients according to their risk for a positive scan. Omitting scans in low risk patients could substantially reduce costs. No significant financial relationships to disclose.
Breast cancer incidence among young women of urban China (Shanghai) and in Canada: Implications for prevention.
Authors: Joseph Ragaz, Andy Coldman, Joel Fox, Kenneth S. Wilson, Shayan Shakeraneh, Ying Zheng, John Joseph Spinelli, Pingping Bao, Hubert Wong, Jory S Simpson, Xi-Chun Hu, Jian Guo Chen
Journal: Journal of Clinical Oncology (2014)

1576 Background: Objective of this study: to evaluate, in Urban China and Canada, the long-term BrCa incidence trends, with emphasis on rates among young women age <50. Shanghai, one of the largest regions of Urban China, enjoyed since the late 1970’s rapid rates of westernization, i.e. confluence of western lifestyles, urbanization and industrialization. While a good association between the westernization and BrCa incidence has been reported in past studies, BrCa age-specific incidence analyses comparing urban China to western regions such as Canada, are not available. Methods: Data were received from Shanghai Municipal Centre for Disease Control and Prevention and from the Public Health Agency of Canada based on the Canadian Cancer Registry database at Statistics Canada. For each region, 5-year age specific BrCa incidence rates [ASIRs] in 5 year cohorts starting at age 35 were estimated and expressed as percent difference between years 1973-79 [baseline, 100%] and the last five years 2000-2004. ASIRs were age-standardized annual new incident cases per 100,000 population, and standardized using the 1960 world population as reference. Results: See Table. Conclusions: For any age group [including those age >65], ASIR increases were much greater in urban Shanghai than in Canada, but they were particularly dramatic for the very young age 35-39. Incidence rates were however still very high also for the whole group of young women age 40-60. As most women in these young age groups of urban China, as in the western countries, receive [western] BrCa diagnostic and therapeutic approaches, a systematic implementation of BrCa preventive strategies and their larger scale research will be required, particular targeting young adolescent women or school age girls. Our data suggest that these are the age groups who are at sizable risk of subclinical carcinogenesis related to western life-style, and for whom prevention research and interventions may have most meaningful cost/benefit, and overall impact. Age group at diagnosis ASIR Canada Shanghai 35 – 39 0% +46% 40 – 44 -4% +106% 45 – 49 -1% +170% 50 – 54 +22% +157% 55 – 59 +30% +132% 60 – 64 +32% +85% 65+ +23% +91%
Pathological response rates in 710 operable breast cancer (BC) patients treated by neoadjuvant chemotherapy (NCT), according to immunohistochemichal subtypes of tumours
Authors: P. J. Chollet, C. Abrial, O. Tacca, I. Raoelfils, M. Leheurteur, M. Mouret-Reynier, S. Amat, X. Durando, J. Dauplat, F. Penault-Llorca
Journal: Journal of Clinical Oncology (2007)

10579 Background: Pathological responses rates were studied in 710 women with stage II-III operable BC treated between 1982 and 2004. A pathological review was conducted to assess the residual disease in breast and nodes according to Chevallier's classification (Am J Clin Oncol 1993) and patients repartited according to 3 tumour phenotypes: Her2+ (Her2+ phenotype), Her2-HR+ (Hormonal Receptor; luminal phenotype) and Her2-HR- (triple negative phenotype). Methods: Median diameter of the invasive tumour was 40 mm [10–130]. 555 (78%) patients had a canalar, 90 (13%) a lobular, 18 (2.5%) a mixed or invasive carcinoma, 36 (5%) neoplasic cells only and 11 (1.5%) another carcinoma. 25.6% of the tumours were grade III SBR. The median number of NCT courses was 6 [1–9] followed by a surgery for 92%, a radiotherapy for 95%, an adjuvant chemotherapy for 17% and/or an hormonotherapy for 52%. A breast evaluation was realized before, during and after NCT. Results: Overall response rate was 68% (16% complete). The complete pathological response (pCR) rate was 14.2% according to Chevallier's classification. On 656 patients operated, 470 (72%) had a conservative surgery. On 520 patients with an axillary dissection, 272 (52.3%) had involved nodes. After a median follow-up of 93 months, Disease-Free Survival (DFS) and Overall Survival (OS) at 120 months were 54.9% and 66.5%, respectively. According to tumour's phenotype, the pCR rate (Chevallier's classes 1+2) was: 24.5% in Her2+ phenotype, 14.8% in triple negative phenotype and 4.4% in luminal phenotype. These results showed that: -the pCR was three-fold more frequent in Her-2+ phenotype than in luminal one (p = 3.5.10 -5 ) -the pCR was two-fold more frequent in triple negative phenotype than in luminal one (p = 3.10 -3 ) -no significant pCR difference was found between Her2+ phenotype and triple negative one Furthermore, a significantly better DFS was found for luminal phenotype; DFS was intermediate for triple negative phenotype, and lower for Her2+ phenotype. Conclusions: The pCR rates were higher in Her2+ phenotype and in triple negative one. It is important to note that, in this series, most Her2+ patients did not receive any Herceptin treatment. No significant financial relationships to disclose.
ANTECEDENT HYPERTENSION AND MYOCARDIAL INJURY IN PATIENTS WITH REPERFUSED ST-ELEVATION MYOCARDIAL INFARCTION
Authors: Sebastian Reinstadler, Thomas Stiermaier, Charlotte Eitel, Mohammed Saad, Bernhard Metzler, Suzanne de Waha, Georg Fuernau, Steffen Desch, Holger Thiele, Ingo Eitel
Journal: Journal of the American College of Cardiology (2017)
Fatigue is a cause of functional dependence in older cancer survivors
Authors: L. Balducci, A. Luciani, M. Extermann, A. Cantor, P. Jacobsen
Journal: Journal of Clinical Oncology (2006)

8538 Background: The incidence and prevalence of cancer increase with age, but the impact of cancer and its treatment on the function of older cancer survivors is unknown. The aim of the study was to establish the prevalence of fatigue in older cancer patients off chemotherapy and the correlation of fatigue with Instrumental Activities of Daily Living (IADL) and Activities of Daily Living (ADL). Methods: We reviewed the cases of 214 individuals aged 70–90 with different cancers, subsequently processed through the Senior Adult Oncology Program (SAOP) over 4 months. All patients of the SAOP are evaluated for function, depression, comorbidity and fatigue, and all of them have a complete blood count. Depression is assessed with the geriatric depression scale (GDS); comorbidity with the cumulative illness rating scale for geriatrics (CIRS-G), and fatigue with the Fatigue symptom inventory (FSI). Results: We found that 82% of the patients reported some degree of fatigue and in 74% of cases fatigue interfered with their daily activities. The average fatigue severity was 5.38 ± 2.59; the FSI interference score 19.1 ± 16.1, the average number of days fatigued in a week 4.07 ± 2.6. Fatigue severity was positively correlated with CIRS_G score (p = 0.04), creatinine clearance (p = 0.02) performance status (PS) (p &lt; 0.0001), GDS (p = 0.04); ADL (0.02); Minimental status (MMS) (p = 0.05); fatigue interference with Cr Clp = ).005); PD (p = 0.001) ADL (p = 0.02); GDS (p = 0.01), and fatigue frequency with CIRS-G (p = 0.04); Cr CL (p = 0.01), PS (p = 0.0001), ADL (p = 0.03); IADL (p = 0.03), and GDS(0.09). ADL dependence was related to intensity (0.02), interference (0.0001) and days of fatigue; IADL dependence to interference score (p = 0.0001) and days of fatigue (p = 0.017) and GDS to intensity (p = 0.004); interference score (p = 0. 006) and frequency of fatigue. Conclusions: Fatigue is common in long term older cancer survivors, and is associated with functional dependence and depression. Control of fatigue may improve the function of older cancer survivors No significant financial relationships to disclose.
An algorithm for managing bilateral lung masses
Authors: J. R. Roberts, D. Schumaker
Journal: Journal of Clinical Oncology (2004)

7371 Background: Ten percent of patients with NSCLC present with bilateral masses. Often these lesions are considered to be metastatic, but may be benign, or a separate primary. Resection is best for benign lesions or separate primaries, but poor therapy for metastases. We report 36 patients with bilateral lung masses on whom we first performed mediastinoscopy. If mediastinal nodes were benign, we then resected both lesions. The resulting data allow the generation of an algorithm to manage patients with bilateral lung masses. Methods: Seventy patients were gleaned from 115 fifteen patients with bilateral lung masses. The CT reports of these patients were read as highly suspicious for malignancy. After negative mediastinoscopy, 36 patients remained, all of whom underwent bilateral resections. Survival was determined for those with “Same Path” in both lesions, “Different Path”, and “One Benign.” Student's t test was used to compare means, and chi-square to compare proportions. Results: There were no differences in the average age of the patients in the three groups. There were striking differences in the survival between those with one benign lesion and those with the same pathology in both lesions (p=0.004). Those patients with different pathologies in each mass had intermediate survival. Conclusions: Our experience demonstrates that patients with similar pathology in bilateral lung masses have very low survival at 24 months, and should not be treated with resection. Patients with bilateral masses should first undergo staging workup and mediastinoscopy. If those are negative, thoracoscopic wedge resection of the smaller lesion combined with needle aspiration of the larger lesion will identify those patients with identical pathology. The larger mass can then be treated with chemoradiotherapy. Patients who are found to have a benign lesion or different pathology should undergo resection. No significant financial relationships to disclose.
COMPARISON OF 30-DAY READMISSION RATE, COST, AND PREDICTORS IN ATRIAL FIBRILLATION PATIENTS TREATED WITH VERSUS WITHOUT ENDOVASCULAR ABLATION
Authors: Smit Patel, Uvesh Mansuri, Rupak Desai, Neel Patel, Mohit Pahuja, Ronak Soni, Chankrit Sethi, Purav Patel, Vinshi Naz Khan
Journal: Journal of the American College of Cardiology (2017)
Study of the expression of integrin pathway's proteins as predictive markers of response to neoadjuvant chemotherapy in pretreatment biopsies of patients with high-grade osteosarcoma.
Authors: Elizabeth Laurence Cohen-Jonathan Moyal, Sophie Le Guellec, Thomas Filleron, Marie-Bernadette Delisle, Christine Chevreau, Herve Rubie, Marie Pierre Castex, Henri Hubert Roche, Jerome Sales De Gauzy, Paul Bonneviale, Anne Brouchet
Journal: Journal of Clinical Oncology (2012)

10076 Background: Up to now, chemosensitivity to neoadjuvant chemotherapy performed for patients with osteosarcoma is evaluated on the surgical resection by the evaluation of the percentage of necrotic cells. No predictive profile of chemotherapy has been described yet. Because we have previously shown that integrin pathway controls genotoxic-induced cell death and hypoxia via ILK, FAK and RhoB, we hypothesized that the expression of the proteins involved in this pathway in pre-treatment biopsies could be associated with sensitivity to chemotherapy in osteosarcoma. Methods: We studied by immunohistochemistry β1, β3, β5, integrins, ILK, FAK, GSK-3β, RhoB and Ang-2 expression in 36 osteosarcomas biopsies of patients obtained before treatment. All the patients were treated by the SFOP OS94 chemotherapy protocol and underwent wide conservative surgery. Response to preoperative chemotherapy was assessed on the surgical resection by the Rosen’s protocol. An immunoreactive score (IRS) was assessed, combining the percentage of positive tumour cells and staining intensity. We evaluated the correlation of the selected markers expression with response to preoperative chemotherapy and clinical outcome. Results: FAK expression was statistically linked with ILK expression (rho=0.43; p=0.020), β1integrin expression with FAK expression (rho=0.51); p=0.003), RhoB with ILK expression (rho=0.55; p=0.002), and β1 with β3integrin expression (rho=0.70; p&lt;.001), suggesting that a regulation of the integrin pathway that we studied might exist in high grade osteosarcoma. Moreover, the combination of β5 integrin, FAK and GSK-3β discriminated good and poor responder to chemotherapy (89.9%; 95% CI= [77.4;1.00], yielding a sensitivity of 94.1%, a specificity of 85.7% and a diagnostic accuracy of 90.3%. Conclusions: We report for the first time a protein expression profile on pre-treatment biopsies associating β5 integrin FAK and GSK-3β related with a poor response to neoadjuvant chemotherapy. This profile could help to select patients for clinical trials using inhibitors of this pathway in association with chemotherapy.
Proteomic and mRNA Expression Chip Analysis of Acquired TRAIL-Resistance in Human HL60 Myeloid Leukemia Cells.
Authors: Jan Zivny, Pavel Klener, Ondrej Toman, Petr Halada, Robert Ivanek, Tereza Simonova, Ladislav Andera, Emanuel Necas, Jiri Petrak
Journal: Blood (2007)
AORTIC REGURGITATION NEGATIVELY AFFECTS LEFT VENTRICULAR MECHANICS AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Kimi Sato, Arnav Kumar, Brandon Jones, Stephanie Mick, Amar Krishnaswamy, Richard Grimm, Milind Desai, Brian Griffin, L. Leonardo Rodriguez, Samir Kapadia, Zoran Popovic
Journal: Journal of the American College of Cardiology (2017)